![ISPOR 2024 May 5-8, 2024 | Atlanta, GA, USA. Early Registration Rate expires March 28.]({"type":"image" , "src" : "/sda/112343/IJME-March-May.jpg"})
Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Conor Chandler, Henri Folse, Peter Gal, Ameya Chavan, Irina Proskorovsky, Conrado Franco-Villalobos, Yunyang Wang & Alex Ward. (2021) Modeling long-term health and economic implications of new treatment strategies for Parkinson’s disease: an individual patient simulation study. Journal of Market Access & Health Policy 9:1.
Read now
Read now
Alexander S. Wang & Steven A. Gunzler. (2019) Systematic review of the pharmacoeconomics of Parkinson disease medications. Expert Opinion on Pharmacotherapy 20:13, pages 1659-1670.
Read now
Read now
Jesper Jørgensen, Spiros Servos & Panos Kefalas. (2018) The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson’s disease. Journal of Market Access & Health Policy 6:1.
Read now
Read now
Julia Lowin, Kavita Sail, Rakhi Baj, Yash J. Jalundhwala, Thomas S. Marshall, Henrietta Konwea & K. R. Chaudhuri. (2017) The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson’s disease. Journal of Medical Economics 20:11, pages 1207-1215.
Read now
Read now
Gillian Barnett & Adrian C. Williams. (2015) Re: Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson’s Disease in the UK and Germany. Journal of Medical Economics 18:11, pages 858-859.
Read now
Read now
Carmen Rodríguez-Blázquez, Maria João Forjaz, Luis Lizán, Silvia Paz & Pablo Martínez-Martín. (2015) Estimating the direct and indirect costs associated with Parkinson’s disease. Expert Review of Pharmacoeconomics & Outcomes Research 15:6, pages 889-911.
Read now
Read now
Articles from other publishers (22)
Akhil Sasidharan, Bhavani Shankara Bagepally & S Sajith Kumar. (2023) Cost Effectiveness of Deep Brain Stimulation for Parkinson’s Disease: A Systematic Review. Applied Health Economics and Health Policy.
Crossref
Crossref
Fabien Zagnoli, Amélie Leblanc, Irina Viakhireva-Dovganyuk, Jean-Philippe Delabrousse-Mayoux, Alain Pouyet, Marc Ziegler, Laura Sogni, Marie Patat, Régis Bouillot, Marc Vérin, Andrei Arhire, Philippe Barres, Maxime Blondiaux, Jean-Claude Bouffeteau, Jean-Philippe Brandel, Christophe Carel, Giovanni Castelnovo, Marc Coustans, Lucie Courault, Christian Crauser, Isabelle Degaey, Bertrand Degos, Jean-Philippe Delabrousse, Béatrice Denis, Marie-Claude Dourneau, Arnaud Duretete, Jean-Marc François Feve, Erika Follin, Michel Gugenheim, Cécile Hubsch, Nathalie Patte Karsenti, Pierre Louchart, Serge Massengo, José Mejias, Homero Monteiro, Philippe Muh, Bernard Pedespan, Virginie Sattler, Mathieu Sevin, Mélissa Tir, Anne Tirel Badets, Marc Verin, Irina Viakhireva, Elisabeth Vidry & Jean-Charles Wiart. (2023) Feasibility and benefits of home initiation of subcutaneous apomorphine infusion for patients with Parkinson’s disease: the APOKADO study. Journal of Neural Transmission 130:11, pages 1463-1474.
Crossref
Crossref
Rajesh Pahwa, Aristide Merola, Michael Soileau, Ali Alobaidi, A. Simon Pickard, Prasanna L. Kandukuri, Yanjun Bao, John Strezewski, Julia Oddsdottir, Weiwei Xu & David Standaert. (2023) Cost‐Effectiveness of Carbidopa‐Levodopa Enteral Suspension for Advanced Parkinson's Disease in the United States. Movement Disorders.
Crossref
Crossref
Prashanth Lingappa Kukkle, Divyani Garg & Marcello Merello. (2023) Continuous Subcutaneous Infusion Delivery of Apomorphine in Parkinson's Disease: A Systematic Review. Movement Disorders Clinical Practice.
Crossref
Crossref
Judith Dams, Johann-Jacob Zapp & Hans-Helmut König. (2023) Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease: An Updated Methodological Review. PharmacoEconomics.
Crossref
Crossref
Susan H Fox. (2022) Revisiting levodopa for advanced Parkinson's disease. The Lancet Neurology 21:12, pages 1063-1065.
Crossref
Crossref
K. Ray Chaudhuri, A. Simon Pickard, Ali Alobaidi, Yash J. Jalundhwala, Prasanna L. Kandukuri, Yanjun Bao, Julia Sus, Glynn Jones, Christian Ridley, Julia Oddsdottir, Seyavash Najle-Rahim, Matthew Madin-Warburton, Weiwei Xu & Anette Schrag. (2022) The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease in England. PharmacoEconomics 40:5, pages 559-574.
Crossref
Crossref
Jenny M. Norlin, Michael Willis, Ulf Persson, Emelie Andersson, Sven Pålhagen & Per Odin. (2021) Swedish guidelines for device‐aided therapies in Parkinson's disease —Economic evaluation and implementation. Acta Neurologica Scandinavica 144:2, pages 170-178.
Crossref
Crossref
Katarzyna Smilowska, Daniel J. van Wamelen, Tomasz Pietrzykowski, Alexander Calvano, Carmen Rodriguez-Blazquez, Pablo Martinez-Martin, Per Odin & K. Ray Chaudhuri. (2021) Cost-Effectiveness of Device-Aided Therapies in Parkinson’s Disease: A Structured Review. Journal of Parkinson's Disease 11:2, pages 475-489.
Crossref
Crossref
Luca Marsili, Matteo Bologna, Janis M. Miyasaki & Carlo Colosimo. (2021) Parkinson's disease advanced therapies - A systematic review: More unanswered questions than guidance. Parkinsonism & Related Disorders 83, pages 132-139.
Crossref
Crossref
Peter Hagell, Arja Höglund, Carina Hellqvist, Eva-Lena Johansson, Berit Löwed, Anne-Christine Sjöström, Carina Karlberg, Margareth Lundgren, Nil Dizdar, Anders Johansson, Thomas Willows, Johan Rådberg & Filip Bergquist. (2020) Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Parkinson’s disease. Journal of Neurology 267:11, pages 3411-3417.
Crossref
Crossref
Joke M. Dijk, Alberto J. Espay, Regina Katzenschlager & Rob M.A. de Bie. (2020) The Choice Between Advanced Therapies for Parkinson’s Disease Patients: Why, What, and When?. Journal of Parkinson's Disease 10:s1, pages S65-S73.
Crossref
Crossref
Elisa Gomez-Inhiesto, María Teresa Acaiturri-Ayesta, Iker Ustarroz-Aguirre, Diana Camahuali, Maider Urtaran-Laresgoiti, Marisol Basabe-Aldecoa, Roberto Nuño-Solinís & Elena Urizar. (2020) Direct Cost of Parkinson’s Disease: A Real-World Data Study of Second-Line Therapies. Parkinson's Disease 2020, pages 1-6.
Crossref
Crossref
Nafsika Afentou, Johan Jarl, Ulf‐G Gerdtham & Sanjib Saha. (2019) Economic Evaluation of Interventions in Parkinson's Disease: A Systematic Literature Review. Movement Disorders Clinical Practice 6:4, pages 282-290.
Crossref
Crossref
Ilias Thomas, Mevludin Memedi, Jerker Westin & Dag Nyholm. (2019) The effect of continuous levodopa treatment during the afternoon hours. Acta Neurologica Scandinavica 139:1, pages 70-75.
Crossref
Crossref
Manon Auffret, Sophie Drapier & Marc Vérin. (2018) Pharmacological Insights into the Use of Apomorphine in Parkinson’s Disease: Clinical Relevance. Clinical Drug Investigation 38:4, pages 287-312.
Crossref
Crossref
Qi Xu, Monica Langley, Anumantha G Kanthasamy & Manju B Reddy. (2017) Epigallocatechin Gallate Has a Neurorescue Effect in a Mouse Model of Parkinson Disease. The Journal of Nutrition 147:10, pages 1926-1931.
Crossref
Crossref
Johan Virhammar & Dag Nyholm. (2016) Levodopa-carbidopa enteral suspension in advanced Parkinson’s disease: clinical evidence and experience. Therapeutic Advances in Neurological Disorders 10:3, pages 171-187.
Crossref
Crossref
Manon Auffret, Florence Le Jeune, Anne Maurus, Sophie Drapier, Jean-François Houvenaghel, Gabriel Hadrien Robert, Paul Sauleau & Marc Vérin. (2017) Apomorphine pump in advanced Parkinson's disease: Effects on motor and nonmotor symptoms with brain metabolism correlations. Journal of the Neurological Sciences 372, pages 279-287.
Crossref
Crossref
Judith Dams, Monika Balzer‐Geldsetzer, Uwe Siebert, Günther Deuschl, W.M. Michael Schuepbach, Paul Krack, Lars Timmermann, Alfons Schnitzler, Jens‐Peter Reese, Richard Dodel, W.M.M. Schuepbach, J. Rau, K. Knudsen, J. Volkmann, P. Krack, L. Timmermann, T.D. Hälbig, H. Hesekamp, S.M. Navarro, N. Meier, D. Falk, M. Mehdorn, S. Paschen, M. Maarouf, M.T. Barbe, G.R. Fink, A. Kupsch, D. Gruber, G.‐H. Schneider, E. Seigneuret, A. Kistner, P. Chaynes, F. Ory‐Magne, C. Brefel Courbon, J. Vesper, A. Schnitzler, L. Wojtecki, J.‐L. Houeto, B. Bataille, D. Maltête, P. Damier, S. Raoul, F. Sixel‐Doering, D. Hellwig, A. Gharabaghi, R. Krüger, M.O. Pinsker, F. Amtage, J.‐M. Régis, T. Witjas, S. Thobois, P. Mertens, M. Kloss, A. Hartmann, W.H. Oertel, B. Post, H. Speelman, Y. Agid, C. Schade‐Brittinger & G. Deuschl. (2016) Cost‐effectiveness of neurostimulation in Parkinson's disease with early motor complications. Movement Disorders 31:8, pages 1183-1191.
Crossref
Crossref
Judith Dams & Richard Dodel. (2016) An economic evaluation of deep brain stimulation for patients with Parkinson's disease. Movement Disorders 31:8, pages 1122-1124.
Crossref
Crossref
S. Drapier, M. Auffret, M. Vérin & P. Sauleau. (2016) Apomorphine en perfusion sous-cutanée continue dans la maladie de Parkinson : le point de vue clinique. Pratique Neurologique - FMC 7:1, pages 33-39.
Crossref
Crossref